Is Venetoclax/Venetoclax better to be domestically produced or imported?

Venetoclax/Venetoclax (Venetoclax) is an important leukemia-targeted drug. Whether it is better to be domestically produced or imported mainly depends on many factors, including the quality of the drug, its price, the patient's specific condition, and the doctor's advice. Whether it is domestically produced or imported venetoclax, it needs to go through strict quality control and approval procedures to ensure its safety and effectiveness. However, it is understood that there is currently no domestically produced Venetextra available for sale in China, only the imported original version of Venetextra.

Veneclat is a novel orally bioavailableB-cell lymphoma-2 inhibitor with significant clinical activity in the treatment of chronic lymphocytic leukemia. When used alone or in combination with other targeted agents, venetoclax resulted in a high rate of durable responses and undetectable measurable residual disease. Venaclat is unique in that it allows for a fixed duration of 12 months for first-line treatment and 24 months for relapsed/refractory treatment, which has favorable implications for compliance and pharmacoeconomics.

The domestically marketed original drug Venekra has been included in the category B medical insurance, and the price of 100mg*14 tablets per box may be around 2,000 yuan, while the Turkish version of the original drug sold overseas, 100mg*112 tablets per box, is priced at more than 10,000 yuan (the price may fluctuate due to exchange rates). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).